It is known that EGFR promotes TNBC progression through JAK/STAT3 signaling [50], CNDK2A drives TNBC tumorigenesis [51], CCND1 has a prognostic significance in TNBC [52], and the three embryonic markers correlate with stemness, metastasis, tumor relapse, and poor clinical outcomes of TNBC [53]; therefore, we propose that biopsy 693 maintains a tumor signature that is associated with an aggressive behavior which predicts poor clinical outcome. The gene discussed is EGFR; the disease is neoplasm.